Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
ER alpha/NR3A1 Mouse anti-Human, Alexa Fluor™ 350, Clone: ER505, Novus Biologicals™
Mouse Monoclonal Antibody
Supplier: Novus Biologicals NBP233106AF350
SDSDocumentsProduct Certifications Promotions
DescriptionER alpha/NR3A1 Monoclonal specifically detects ER alpha/NR3A1 in Human samples. It is validated for Western Blot, Immunohistochemistry, Immunohistochemistry-Paraffin, Flow (Intracellular).
|Alexa Fluor 350|
|50 mM sodium borate with 0.05% sodium azide|
|Recombinant human ER alpha/NR3A1 alpha protein (aa2-185) (Uniprot: P03372)|
|Western Blot, Flow Cytometry, ELISA, Immunohistochemistry, Immunohistochemistry (Paraffin), Immunohistochemistry (Frozen)|
|Western Blot, Flow Cytometry, ELISA, Immunohistochemistry, Immunohistochemistry-Paraffin, Immunohistochemistry-Frozen|
|ER, ER alpha, Era, ER-alpha, ESRESRA, Estradiol receptor, estrogen receptor, estrogen receptor 1, estrogen receptor alpha, estrogen receptor alpha delta 3*4,56,7*/819-2 isoform, estrogen receptor alpha delta 4 +49 isoform, estrogen receptor alpha delta 4*5,6,7*/654 isoform, NR3A1DKFZp686N23123, Nuclear receptor subfamily 3 group A member 1|
|Protein A or G purified|
|This monoclonal antibody is specific to ER alpha and shows minimal cross-reaction with other members of the family. ER is an important regulator of growth and differentiation in the mammary gland. Presence of ER in breast tumors indicates an increased likelihood of response to anti-estrogen (e.g. tamoxifen) therapy. This monoclonal antibody is excellent for staining of formalin-fixed, paraffin-embedded breast carcinomas.|
|Store at 4°C in the dark.|
Provide Content Correction
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok